KindlyMD (NASDAQ:NAKA) Stock Price Expected to Rise, B. Riley Financial Analyst Says

KindlyMD (NASDAQ:NAKA) had its price objective hoisted by stock analysts at B. Riley Financial from $9.00 to $11.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial’s target price would suggest a potential upside of 33.66% from the company’s current price.

A number of other equities analysts also recently commented on NAKA. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a report on Saturday, May 23rd. TD Cowen boosted their price objective on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, KindlyMD currently has an average rating of “Hold” and a consensus price target of $19.33.

KindlyMD Stock Up 7.2%

Shares of NAKA stock traded up $0.55 during mid-day trading on Thursday, reaching $8.23. The company’s stock had a trading volume of 125,402 shares, compared to its average volume of 197,320. The company’s 50 day simple moving average is $5.04 and its 200-day simple moving average is $6.95. KindlyMD has a 12-month low of $3.33 and a 12-month high of $343.20. The firm has a market capitalization of $147.28 million, a PE ratio of -0.23 and a beta of 15.99.

KindlyMD (NASDAQ:NAKA) last issued its earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. The company had revenue of $35.87 million during the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%. As a group, research analysts anticipate that KindlyMD will post -11.31 EPS for the current fiscal year.

Insider Activity at KindlyMD

In other news, CEO David F. Bailey acquired 32,134 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were acquired at an average price of $5.59 per share, with a total value of $179,629.06. Following the acquisition, the chief executive officer directly owned 32,134 shares in the company, valued at approximately $179,629.06. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought a total of 41,904 shares of company stock worth $235,231 in the last three months. 24.49% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On KindlyMD

A number of hedge funds and other institutional investors have recently modified their holdings of NAKA. J. Derek Lewis & Associates Inc. purchased a new position in KindlyMD during the fourth quarter valued at approximately $167,000. Virtu Financial LLC acquired a new position in shares of KindlyMD during the fourth quarter valued at about $151,000. Invesco Ltd. bought a new stake in shares of KindlyMD in the 4th quarter worth approximately $211,000. NewEdge Advisors LLC bought a new position in KindlyMD during the fourth quarter worth about $316,000. Finally, Saba Capital Management L.P. acquired a new stake in KindlyMD in the 4th quarter valued at $1,399,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.